07:00 , Mar 10, 2008 |  BC Week In Review  |  Clinical News

Chronocort: Phase II data

Data from a U.S. Phase II trial showed that in 14 patients receiving Chronocort, overnight cortisol profiles were closer to the normal physiological profile than in those receiving conventional, immediate-release hydrocortisone. The majority of Chronocort-...
07:00 , Oct 22, 2007 |  BC Week In Review  |  Company News

Cardiff Biologicals Ltd., Cardiff, Morvus deal

Eli Lilly and Co. (LLY, Indianapolis, Ind.) markets Gemzar gemcitabine to treat breast cancer, non-small cell lung cancer (NSCLC) and pancreatic cancer, and advanced relapsed ovarian cancer in combination with carboplatin. Cardiff Biologicals Ltd. ,...
07:00 , Sep 3, 2007 |  BC Week In Review  |  Clinical News

Chronocort: Phase II started

PQS began an open-label, crossover, U.S. Phase II trial (Study 004) in 12 patients to compare once-daily Chronocort vs. thrice-daily immediate-release hydrocortisone. Patients will receive a minimum of 7 days of the immediate-release version followed...
07:00 , Aug 6, 2007 |  BC Week In Review  |  Clinical News

Chronocort: Phase III start

In 1Q08, PQS expects to begin a double-blind, European and U.S. Phase III trial (Study 006) in about 250 patients to evaluate corticosteroids plus either Chronocort or standard of care. Phoqus Group plc (LSE:PQS), West...
07:00 , Aug 6, 2007 |  BC Week In Review  |  Clinical News

Chronocort: Phase III start

In 1Q08, PQS expects to begin an open-label, European and U.S. Phase III trial (Study 005) in about 60 to evaluate corticosteroids plus either Chronocort or standard treatment. Phoqus Group plc (LSE:PQS), West Malling, U.K....
07:00 , Aug 6, 2007 |  BC Week In Review  |  Clinical News

Chronocort: Phase II start

This month, PQS will begin an open-label, U.S. Phase II trial (Study 004) in 130 patients to evaluate corticosteroids plus either Chronocort or standard of care. NIH will sponsor the trial. Phoqus Group plc (LSE:PQS),...
07:00 , Jun 4, 2007 |  BC Week In Review  |  Clinical News

Chronocort regulatory update

The EC granted Orphan Drug designation for Chronocort to treat adrenal insufficiency. The modified-release hydrocortisone tablet also has Orphan Drug designation in the EU for congenital adrenal hyperplasia. BFN's Diurnal Ltd. subsidiary partnered Chronocort with...
07:00 , May 21, 2007 |  BioCentury  |  Finance

Ebb & Flow

Novartis has launched a new venture fund, the $200 million Novartis Option Fund , which will give the pharmaceutical company a first option to license a very early stage program at portfolio companies. "As I...
07:00 , May 14, 2007 |  BC Week In Review  |  Company News

Biofusion plc, University of Sheffield infectious news

The university spun out Medella Therapeutics Ltd. (Sheffield, U.K.). Medella has exclusive rights to the university's IP covering MAbs targeting adrenomedullin to treat cancer. The newco has six research-stage candidates. BFN, which invested £320,000 ($640,000)...
08:00 , Feb 5, 2007 |  BC Week In Review  |  Company News

Biofusion plc, University of Sheffield deal

The university spun out Absynth Biologics Ltd. (Sheffield, U.K.), which will use the university’s antibody-recognition technology to develop vaccines and antibodies against S. aureus, including methicillin-resistant S. aureus (MRSA). BFN, which invested £325,000 ($637,000) in...